- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jill Jarecki Discusses Whether Gender Affects SMA Severity
Jill Jarecki, PhD, chief scientific officer at Cure SMA explained the current data and potential for gender to impact the severity spinal muscular atrophy (SMA).
Jill Jarecki, PhD, chief scientific officer at Cure SMA explained the current data and potential for gender to impact the severity spinal muscular atrophy (SMA).
Transcript
What are your thoughts regarding whether gender has any effects on disease severity?
Jarecki: So, I think that it's been discussed in our community a few times whether gender has any effects on disease severity. However, from our data that CureSMA, currently has, we see that SMA affects both sexes equally. Our patient reported database where we have over 8000 patient records and from our clinical database, we see no evidence that severity is based on sex.
Generally, our data shows a 50/50 split of male and female patients in the SMA community. However, it's possible that there are more nuanced differences in severity that we can't detect through our data at this point.
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
